Evidence map›Paper›PMID 34588590›Full record

Observational studyScientific reports2021

Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs.

Clovis Boibessot, France-Hélène Joncas, Aerin Park, Zohra Berrehail, Jean-François Pelletier, Typhaine Gris, Alain Bergeron, Paul Toren

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Harnessing the Utility ofFrontiers in oncology · 2022
    Review
  7. Article
  8. Article
  9. Sex steroid modulation of macrophages within the prostate tumor microenvironment.American journal of clinical and experimental urology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Clovis BoibessotLaboratoire d'Uro-Oncologie Expérimentale, Centre de recherche du CHU de Québec-Université Laval, Axe Oncologie, 10 McMahon, rm 0877, Quebec, QC, G1R 3S1, Canada.
France-Hélène JoncasLaboratoire d'Uro-Oncologie Expérimentale, Centre de recherche du CHU de Québec-Université Laval, Axe Oncologie, 10 McMahon, rm 0877, Quebec, QC, G1R 3S1, Canada.
Aerin ParkLaboratoire d'Uro-Oncologie Expérimentale, Centre de recherche du CHU de Québec-Université Laval, Axe Oncologie, 10 McMahon, rm 0877, Quebec, QC, G1R 3S1, Canada.
Zohra BerrehailLaboratoire d'Uro-Oncologie Expérimentale, Centre de recherche du CHU de Québec-Université Laval, Axe Oncologie, 10 McMahon, rm 0877, Quebec, QC, G1R 3S1, Canada.
Jean-François PelletierLaboratoire d'Uro-Oncologie Expérimentale, Centre de recherche du CHU de Québec-Université Laval, Axe Oncologie, 10 McMahon, rm 0877, Quebec, QC, G1R 3S1, Canada.
Typhaine GrisLaboratoire d'Uro-Oncologie Expérimentale, Centre de recherche du CHU de Québec-Université Laval, Axe Oncologie, 10 McMahon, rm 0877, Quebec, QC, G1R 3S1, Canada.
Alain BergeronLaboratoire d'Uro-Oncologie Expérimentale, Centre de recherche du CHU de Québec-Université Laval, Axe Oncologie, 10 McMahon, rm 0877, Quebec, QC, G1R 3S1, Canada.
Paul TorenLaboratoire d'Uro-Oncologie Expérimentale, Centre de recherche du CHU de Québec-Université Laval, Axe Oncologie, 10 McMahon, rm 0877, Quebec, QC, G1R 3S1, Canada. paul.toren@crchudequebec.ulaval.ca.
Université Laval · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Within the prostate tumor microenvironment (TME) there are complex multi-faceted and dynamic communication occurring between cancer cells and immune cells. Macrophages are key cells which infiltrate and surround tumor cells and are recognized to significantly contribute to tumor resistance and metastases. Our understanding of their function in the TME is commonly based on in vitro and in vivo models, with limited research to confirm these model observations in human prostates. Macrophage infiltration was evaluated within the TME of human prostates after 72 h culture of fresh biopsies samples in the presence of control or enzalutamide. In addition to immunohistochemistry, an optimized protocol for multi-parametric evaluation of cellular surface markers was developed using flow cytometry. Flow cytometry parameters were compared to clinicopathological features. Immunohistochemistry staining for 19 patients with paired samples suggested enzalutamide increased the expression of CD163 relative to CD68 staining. Techniques to validate these results using flow cytometry of dissociated biopsies after 72 h of culture are described. In a second cohort of patients with Gleason grade group ≥ 3 prostate cancer, global macrophage expression of CD163 was unchanged with enzalutamide treatment. However, exploratory analyses of our results using multi-parametric flow cytometry for multiple immunosuppressive macrophage markers suggest subgroup changes as well as novel associations between circulating biomarkers like the neutrophil to lymphocyte ratio (NLR) and immune cell phenotype composition in the prostate TME. Further, we observed an association between B7-H3 expressing tumor-associated macrophages and the presence of intraductal carcinoma. The use of flow cytometry to evaluate ex vivo cultured prostate biopsies fills an important gap in our ability to understand the immune cell composition of the prostate TME. Our results highlight novel associations for further investigation.

Indexed as

AgedAndrogen AntagonistsBenzamidesBiomarkers, TumorCells, CulturedChemotherapy, AdjuvantDrug Evaluation, PreclinicalFlow CytometryHumansMaleMiddle AgedNitrilesPhenylthiohydantoinPrimary Cell CultureProstateProstatectomyAndrogen AntagonistsBenzamidesBiomarkers, TumorenzalutamideNitrilesPhenylthiohydantoin

Identifiers

PMID34588590
PMCPMC8481239
OpenAlexW3201737725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.